Aqilion presents new results from the AQ312 program (oral Ahr agonist) during UEG Week in Vienna October 14, 2024
UNION therapeutics announce results from the ADESOS Phase 2b study in atopic dermatitis confirming the potential of orismilast as a first-in-class safe and efficacious oral treatment September 26, 2024
New Galderma Data Demonstrating Nemolizumab’s Long-term Efficacy and Safety in Atopic Dermatitis and Durability in Prurigo Nodularis to Be Shared During Three Oral Presentations September 25, 2024